{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:41:23Z","timestamp":1794966083661,"version":"4.9.1"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T00:00:00Z","timestamp":1604448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["GSK 207382"],"award-info":[{"award-number":["GSK 207382"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Adelphi Real World"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To describe how patients with primary SS (pSS) and systemic organ involvement are classified and clustered in routine practice.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This multinational, cross-sectional survey of real-world quantitative data was conducted across Europe and the US. Rheumatologists who treated seven or more adult patients per month with pSS and current\/past systemic manifestations undertook a survey before completing a patient record form capturing demographic, clinical and treatment information for their next six eligible patients. Patients with a completed patient record form were invited to complete a patient self-completion questionnaire capturing insights into their disease and treatment. Subgroups were defined by physicians\u2019 assessment of disease severity; clusters were derived based on key clinical characteristics using latent class analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Rheumatologists completed 316 physician surveys and 1879 patient record forms; 888 patients completed the patient self-completion questionnaire. pSS severity reflected organ involvement and symptomatology. Latent class analysis produced five clusters distinguished by the organ systems involved and the presence of pain and fatigue symptoms at the time of the survey. A minority of patients [n\u2009=\u200967 (4%)] were categorized with multiple organ involvement and the highest frequency of pain and fatigue. A total of 324 patients (17%) were categorized as \u2018low burden\u2019. The remaining three clusters exhibited high frequencies of articular involvement but were distinguished by the extent of other organ system involvement.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Cluster analysis using a real-world cohort of patients with pSS and systemic organ involvement highlights the heterogeneous presentation of patients with pSS and confirms the importance of pain and fatigue as well as organ involvement when determining disease burden.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaa508","type":"journal-article","created":{"date-parts":[[2020,7,23]],"date-time":"2020-07-23T19:14:24Z","timestamp":1595531664000},"page":"1871-1881","source":"Crossref","is-referenced-by-count":21,"title":["Burden of illness among subgroups of patients with primary Sj\u00f6gren\u2019s syndrome and systemic involvement"],"prefix":"10.1093","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8591-1396","authenticated-orcid":false,"given":"Kerry","family":"Gairy","sequence":"first","affiliation":[{"name":"Value Evidence & Outcomes, GlaxoSmithKline, Brentford, Middlesex, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Knight","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Adelphi Group, Macclesfield, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Papa","family":"Anthony","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Adelphi Group, Macclesfield, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Hoskin","sequence":"additional","affiliation":[{"name":"Adelphi Real World, Adelphi Group, Macclesfield, Cheshire, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,11,4]]},"reference":[{"key":"2021040620372239800_keaa508-B1","doi-asserted-by":"crossref","first-page":"651","DOI":"10.2217\/ijr.12.64","article-title":"Serologic features of primary Sj\u00f6gren\u2019s syndrome: clinical and prognostic correlation","volume":"7","author":"Garcia-Carrasco","year":"2012","journal-title":"Int J Clin Rheumtol"},{"key":"2021040620372239800_keaa508-B2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1385\/CRIAI:25:1:89","article-title":"Immunopathogenesis of Sj\u00f6gren\u2019s syndrome","volume":"25","author":"Borchers","year":"2003","journal-title":"Clin Rev Allergy Immunol"},{"key":"2021040620372239800_keaa508-B3","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1136\/annrheumdis-2014-205375","article-title":"Epidemiology of primary Sj\u00f6gren\u2019s syndrome: a systematic review and meta-analysis","volume":"74","author":"Qin","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2021040620372239800_keaa508-B4","doi-asserted-by":"crossref","first-page":"191","DOI":"10.7150\/ijms.17718","article-title":"Reviewing primary Sj\u00f6gren\u2019s syndrome: beyond the dryness \u2013 from pathophysiology to diagnosis and treatment","volume":"14","author":"Both","year":"2017","journal-title":"Int J Med Sci"},{"key":"2021040620372239800_keaa508-B5","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1093\/rheumatology\/kev200","article-title":"Characterization of systemic disease in primary Sj\u00f6gren\u2019s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements","volume":"54","author":"Ramos-Casals","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2021040620372239800_keaa508-B6","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.12688\/f1000research.8352.1","article-title":"Recent advances in primary Sj\u00f6gren\u2019s syndrome","volume":"5","author":"Holdgate","year":"2016","journal-title":"F1000Res"},{"key":"2021040620372239800_keaa508-B7","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/art.24311","article-title":"Prevalence, severity, and predictors of fatigue in subjects with primary Sj\u00f6gren\u2019s syndrome","volume":"59","author":"Segal","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2021040620372239800_keaa508-B8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1177\/1759720X17746319","article-title":"Management of primary Sj\u00f6gren\u2019s syndrome: recent developments and new classification criteria","volume":"10","author":"Del Papa","year":"2018","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2021040620372239800_keaa508-B9","first-page":"354","article-title":"The diagnosis and treatment of Sj\u00f6gren\u2019s syndrome","volume":"114","author":"Stefanski","year":"2017","journal-title":"Dtsch Arztebl Int"},{"key":"2021040620372239800_keaa508-B10","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/acr.21956","article-title":"Pain severity and neuropathic pain symptoms in primary Sj\u00f6gren\u2019s syndrome: a comparison study of seropositive and seronegative Sj\u00f6gren\u2019s syndrome patients","volume":"65","author":"Segal","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021040620372239800_keaa508-B11","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1007\/s00296-014-3008-0","article-title":"Illness perceptions and psychological distress associated with physical health-related quality of life in primary Sj\u00f6gren\u2019s syndrome compared to systemic lupus erythematosus and rheumatoid arthritis","volume":"34","author":"Kotsis","year":"2014","journal-title":"Rheumatol Int"},{"key":"2021040620372239800_keaa508-B12","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/rheumatology\/kel155","article-title":"Direct healthcare costs and predictors of costs in patients with primary Sj\u00f6gren\u2019s syndrome","volume":"46","author":"Callaghan","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"2021040620372239800_keaa508-B13","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.3899\/jrheum.090734","article-title":"Estimating indirect costs in primary Sj\u00f6gren\u2019s syndrome","volume":"37","author":"Bowman","year":"2010","journal-title":"J Rheumatol"},{"key":"2021040620372239800_keaa508-B14","first-page":"1259","article-title":"Validation of the Sicca Symptoms Inventory for clinical studies of Sj\u00f6gren\u2019s syndrome","volume":"30","author":"Bowman","year":"2003","journal-title":"J Rheumatol"},{"key":"2021040620372239800_keaa508-B15","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/ard.57.1.20","article-title":"Weak association between subjective symptoms or and objective testing for dry eyes and dry mouth: results from a population based study","volume":"57","author":"Hay","year":"1998","journal-title":"Ann Rheum Dis"},{"key":"2021040620372239800_keaa508-B16","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jaut.2013.12.010","article-title":"Outcome measures for primary Sj\u00f6gren\u2019s syndrome: a comprehensive review","volume":"51","author":"Seror","year":"2014","journal-title":"J Autoimmun"},{"key":"2021040620372239800_keaa508-B17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.36469\/9807","article-title":"Clinical and cost burden of primary Sj\u00f6gren\u2019s syndrome: descriptive analysis using a US Administrative Claims Database","volume":"5","author":"Perera","year":"2018","journal-title":"J Health Econ Outcomes Res"},{"key":"2021040620372239800_keaa508-B18","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sj\u00f6gren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sj\u00f6gren\u2019s syndrome","volume":"69","author":"Seror","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2021040620372239800_keaa508-B19","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sj\u00f6gren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sj\u00f6gren\u2019s syndrome","volume":"70","author":"Seror","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"2021040620372239800_keaa508-B20","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1185\/03007990802457040","article-title":"Real-world physician and patient behaviour across countries: Disease-Specific Programmes \u2013 a means to understand","volume":"24","author":"Anderson","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"2021040620372239800_keaa508-B21","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1016\/S2665-9913(19)30042-6","article-title":"Symptom-based stratification of patients with primary Sj\u00f6gren\u2019s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials","volume":"1","author":"Tarn","year":"2019","journal-title":"Lancet Rheumatol"},{"key":"2021040620372239800_keaa508-B22","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4161\/mabs.23684","article-title":"Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human","volume":"5","author":"Shah","year":"2013","journal-title":"MAbs"},{"key":"2021040620372239800_keaa508-B23","year":"2019"},{"key":"2021040620372239800_keaa508-B24","doi-asserted-by":"crossref","first-page":"e000022","DOI":"10.1136\/rmdopen-2014-000022","article-title":"EULAR Sj\u00f6gren\u2019s syndrome disease activity index (ESSDAI): a user guide","volume":"1","author":"Seror","year":"2015","journal-title":"RMD Open"},{"key":"2021040620372239800_keaa508-B25","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1007\/s00296-018-4013-5","article-title":"Factors associated with severe dry eye in primary Sj\u00f6gren\u2019s syndrome diagnosed patients","volume":"38","author":"Fernandez Castro","year":"2018","journal-title":"Rheumatol Int"},{"key":"2021040620372239800_keaa508-B26","article-title":"Eligibility for clinical trials in primary Sj\u00f6gren\u2019s syndrome: lessons from the UK Primary Sj\u00f6gren\u2019s Syndrome Registry [supplemental appendix]"},{"key":"2021040620372239800_keaa508-B27","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1093\/rheumatology\/kez578","article-title":"Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sj\u00f6gren\u2019s syndrome","volume":"59","author":"Brito-Zeron","year":"2020","journal-title":"Rheumatology"},{"key":"2021040620372239800_keaa508-B28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/rheumatology\/ket349","article-title":"Systemic involvement in primary Sj\u00f6gren\u2019s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry)","volume":"53","author":"Ramos-Casals","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"2021040620372239800_keaa508-B29","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2012-202863","article-title":"Health-related utility values of patients with primary Sj\u00f6gren\u2019s syndrome and its predictors","volume":"73","author":"Lendrem","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2021040620372239800_keaa508-B30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2021040620372239800_keaa508-B31"},{"key":"2021040620372239800_keaa508-B32","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1002\/acr.21738","article-title":"Impaired functional status in primary Sj\u00f6gren\u2019s syndrome","volume":"64","author":"Hackett","year":"2012","journal-title":"Arthritis Care Res (Hoboken"},{"key":"2021040620372239800_keaa508-B33","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/acr.22263","article-title":"Primary Sj\u00f6gren\u2019s syndrome: fatigue is an ever-present, fluctuating, and uncontrollable lack of energy","volume":"66","author":"Mengshoel","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021040620372239800_keaa508-B34","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1136\/annrheumdis-2011-201009","article-title":"Autonomic symptoms are common and are associated with overall symptom burden and disease activity in primary Sj\u00f6gren\u2019s syndrome","volume":"71","author":"Newton","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"2021040620372239800_keaa508-B35","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/acr.21991","article-title":"European League Against Rheumatism Sj\u00f6gren\u2019s Syndrome Disease Activity Index and European League Against Rheumatism Sj\u00f6gren\u2019s Syndrome Patient-Reported Index: a complete picture of primary Sj\u00f6gren\u2019s syndrome patients","volume":"65","author":"Seror","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2021040620372239800_keaa508-B36","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/rheumatology\/ker208","article-title":"Fatigue and depression predict physician visits and work disability in women with primary Sj\u00f6gren\u2019s syndrome: results from a cohort study","volume":"51","author":"Westhoff","year":"2012","journal-title":"Rheumatology (Oxford"},{"key":"2021040620372239800_keaa508-B37","first-page":"S82","article-title":"Fatigue in Sj\u00f6gren\u2019s syndrome: relationship with fibromyalgia, clinical and biologic features","volume":"28","author":"Priori","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2021040620372239800_keaa508-B38","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2013-204615","article-title":"Validation of EULAR primary Sj\u00f6gren\u2019s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI)","volume":"74","author":"Seror","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/4\/1871\/36913012\/keaa508.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/rheumatology\/article-pdf\/60\/4\/1871\/36913012\/keaa508.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,6]],"date-time":"2021-04-06T23:40:02Z","timestamp":1617752402000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/60\/4\/1871\/5956233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,4]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,11,4]]},"published-print":{"date-parts":[[2021,4,6]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaa508","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,11,4]]}}}